Tissue Regenix Group - Change of Adviser
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or the 'Group')
Change of Adviser
Tissue Regenix (AIM: TRX), the regenerative medical device company, is pleased to announce the appointment of finnCap Ltd as its Nominated Adviser and Broker with immediate effect.
For more information:
|
Tissue Regenix Group plc |
||||||
|
|
Via Walbrook PR |
|||||
|
|
|
|||||
|
Tel: +44(0)20 7220 500 |
|||||
|
Walbrook PR (Financial PR & IR) |
Tel: +44(0)20 7933 8780 |
|||||
|
|
||||||
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of high quality, innovative tissue scaffolds, which can enhance healing opportunities in defects created by trauma and disease. CellRight®'s human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.
AIM Rule 17 Disclosure
The Company announces the following additional director disclosures pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Regarding the directorship disclosures made in
Regarding the disclosures made in
In addition to the current directorship of Consort Medical plc ("Consort Medical") that was disclosed at the time of his appointment,
AESICA BC Limited
AESICA Formulation Development Limited
AESICA Holdco Limited
AESICA M1 Limited
AESICA M2 Limited
AESICA Queensborough Limited
AESICA Trustee Company Limited
Bespak Europe Limited
Bespak Finance Limited
Bespak Holdings Limited
Consort Medical Finance 2010 Limited
Consort Medical Finance Limited
Consort Medical Limited
Integrated Aluminium Components Limited
Medical House (ASI) Limited
Medical House Products Limited
Pharmaron Manufacturing Services (UK) Ltd
The Medical House Group Limited
The Medical House Limited
In addition to the directorship disclosures made in
Vectura Group Limited (previously Vectura Group plc)
Vectura Limited
Vectura Delivery Devices Limited
Shervanthi Homer-Vanniasinkam
In addition to the disclosures made in Shervanthi Homer-Vanniasinkam's announcement of appointment on
Directorship held at time of appointment to Tissue Regenix: Holistx Limited
Directorship held within previous 5 years at time of appointment to Tissue Regenix: The Vascular Society
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE